GlobeNewswire

With the release of Version 7.1, Sciforma launches Connections, a smart feature providing a holistic view of the enterprise

Dela

Sciforma 7.1 brings new level of agility to digital transformation

 

SAN JOSE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Sciforma, a leading provider of Project and Portfolio Management (PPM) software for large and mid-size companies, announced today the latest version of its PPM solution: Sciforma 7.1. Representing a new generation in PPM systems connecting people, teams and project data, Sciforma 7.1 helps keep all stakeholders constantly aware of the overall context, so they can anticipate any disruptions that would impact goals and objectives.

For any project manager, managing unforeseen changes can be immensely challenging, even for Agile teams. Team members are often involved in multiple projects at the same time, which exposes the entire team to the difficulty of factoring in external elements. Yet, most PPM software continues treating project managers as if they were working in silos, ignoring what is happening elsewhere in their organizations.

With "Connections," Sciforma gives project, product and program managers instant visibility into their surroundings.  The potential impact of previous, ongoing or future initiatives from other parts of the organization can be constantly factored into planning.

"With Sciforma 7.1's new Connections feature, people, teams and project data are all interconnected," explains Fabien Herelle, Sciforma Vice President of Solutions. "Managers can very easily track a project's history and predict its course in both the technical and business contexts."

Dan Stang, Gartner Research VP, wrote, "Project management offices often struggle to set the right priorities and achieve the desired outcomes and value from their work efforts. As program and portfolio management leaders transform their PMOs to support digital, they should use an approach that ends with projects and starts with context." [1]

"CONNECTIONS" BENEFITS:

  • Identify any other business cases, projects, products or programs that share the same life cycle, budget goals or scope, so that they are systematically considered when changes to scope or dates are made.

  • Constantly visualize their environment in the greater context, so that interconnections and dependencies with other parts of the organization are taken into account when making decisions.

  • Leverage status reports to understand the status of any of those connected elements. Potential slips and associated risks can be anticipated and the right actors contacted, to enable everyone to adapt to upcoming changes.

  • Easily communicate through Notes with the other stakeholders.

  • Conduct program or product review meetings with dashboards consolidating and highlighting key elements from the connected projects.

  • Easily keep track of the arc of a project: why it was launched; the how and why of decisions made along the way; and the objectives agreed upon to stay on target.

WHAT'S NEW IN SCIFORMA 7.1? 

  • Stronger Multi-Methodologies Integration in Project Planning and Management: Project Managers can use the Sciforma solution to work either using Agile methodologies, more classic Waterfall approaches, critical chain, or other leading approaches - all at no additional cost.

  • New capabilities to create assessment and scoring templates tailored to the organization's needs in Idea Management.

  • New Resource Management techniques to allocate resources to projects, based on organization's maturity.

  • New Budget-driven Ranking and drill-down capabilities for Simulation in Portfolio Management.

  • Completely redesigned Work Management featuring more collaborative capabilities, Inbox and Kanban views for managing issues, actions, deliverables, risks, etc. and seamlessly moving them around  business cases, projects, products, programs, and portfolios.

  • Fast and easy set up: The Sciforma 7.1 PPM solution is both comprehensive and very fast to install. The complete configuration can be done in a matter of days. It is designed for full scalability, so project teams across the organization and across the globe can instantly tailor it to the methodologies they want to use.

Feedback from customers using early release versions of 7.1 is excellent. "Having been one of the first to use Sciforma 7.1, we're pleased to report that it is very intuitive and easy to use," confirms Amirouche Sellam, PMO Director of Belron-Canada.

Total benefits for PPM users include savings from:

  • Reduced project failure rates;
  • Reduced project cycle times;
  • Reduced costs overruns;
  • Avoiding low/no-value projects;
  • Eliminating PM time spent on low-value tasks.

In fact with Sciforma 7.1, companies running 50 and more projects per year can benefit from millions in savings. (Contact us to discuss your potential ROI based on your specific situation.)

PRICE/AVAILABILITY

Sciforma 7.1 is available for immediate purchase. Please contact a Sciforma representative or reseller for pricing information.

[1] Gartner, Real Project Prioritization Needs Context to Yield Real Results, Analyst(s): Daniel B. Stang , Published: 22 November 2017 ID: G00343401

About Sciforma
Sciforma is one of the largest providers of Portfolio & Project Management software, delivering solutions to quarter million users worldwide since 1982. The company offers flexible and easy-to-use multi-platform project management and project portfolio management software solutions. Businesses that have multiple projects from multiple clients (including internal customers) need to be able to prioritize efforts that will bring the best results to the company. The configurable Sciforma PPM solution provides project managers and executives the ability to analyze investments, plan capacity, manage risks, and control expenses better.  For more information, visit: www.sciforma.com. Follow us on LinkedIn and on Twitter @Sciforma.

Contact:

Valerie Zeller, CMO
vzeller@sciforma.com

Maryse Camelan
maryse@mc3.co
+1 425 985 2121




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sciforma Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Oboya participates in China International Import Expo1.11.2018 15:00Pressmeddelande

Newsletter Lerum, 1th November 2018 Oboya Horticulture Industries AB (publ) ("Oboya"), a global manufacturer and supplier of products and services for the cultivation industry, will participate in China International Import Expo in Shanghai, China. China International Import Expo (CIIE) is a six-day fair held from November 5 to November 10, 2018 at the National Convention & Exhibition Center in Shanghai, China. This fair brings together companies, exhibitors and professional buyers from all over the world. The fair creates new channels for companies from different countries and regions and provides the opportunity to do business, strengthen cooperation and promote trade. Oboya's strategy is to work globally in the various markets in the cultivation and flower industry, which it's important for Oboya to participate in the major trade shows. Oboya has its own booth at the fair and will show/marketing the European cultivation products and technology to the Chinese market. The purpose of t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum